At least one psychedelic biotech company trading below $15/share as of May 2026 will publicly announce a strategic review, merger exploration, or distressed partnership by Q3 2026.

Two major psychedelic biotech companies (COMPASS and Mind Medicine) trade at rock-bottom stock prices with no approval in sight and shrinking cash. When boards see money running out and no good news coming, they typically announce they're 'exploring strategic options'—which usually means merger talks, asset sales, or shutdown. This is the standard corporate signal for desperation.

CMPS (~$11.89) and MMED (~$10.96) are both cash-burning without near-term approval catalysts following the MDMA CRL. Board fiduciary duty and institutional investor pressure create structural incentives for strategic review announcements at this valuation level. The 12-month cash runway threshold for multiple companies in this cohort is approaching. A strategic review announcement is the standard pre-M&A signal and is a falsifiable, observable corporate disclosure.